Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|
Sep. 30, 2019 |
Sep. 30, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Dec. 31, 2018 |
|
NCI - equity (deficit) - beginning of period | $ (161,512) | ||||
Net loss attributable to NCI | $ (186,349) | $ (32,431) | (500,622) | $ (113,631) | |
NCI - equity (deficit) - end of period | (520,356) | (520,356) | $ (161,512) | ||
Noncontrolling Interest [Member] | |||||
NCI - equity (deficit) - beginning of period | (161,512) | ||||
Investment in majority-owned subsidiary | 1,812 | ||||
Net loss attributable to NCI | (500,622) | (204,072) | |||
Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation | 141,778 | 40,748 | |||
NCI - equity (deficit) - end of period | $ (520,356) | $ (520,356) | $ (161,512) |
X | ||||||||||
- Definition Investment in majority-owned subsidiary. No definition available.
|
X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|